AU2017298648B2 - 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein - Google Patents

1-methylnicotinamide for the treatment of diseases associated with C-reactive protein Download PDF

Info

Publication number
AU2017298648B2
AU2017298648B2 AU2017298648A AU2017298648A AU2017298648B2 AU 2017298648 B2 AU2017298648 B2 AU 2017298648B2 AU 2017298648 A AU2017298648 A AU 2017298648A AU 2017298648 A AU2017298648 A AU 2017298648A AU 2017298648 B2 AU2017298648 B2 AU 2017298648B2
Authority
AU
Australia
Prior art keywords
subject
crp
level
pharmaceutically acceptable
mna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017298648A
Other languages
English (en)
Other versions
AU2017298648A1 (en
Inventor
Eugenio A. Cefali
Jerzy Gebicki
Konrad PALKA
Marzena WIECZORKOWSKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmena SA
Original Assignee
Pharmena SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmena SA filed Critical Pharmena SA
Publication of AU2017298648A1 publication Critical patent/AU2017298648A1/en
Application granted granted Critical
Publication of AU2017298648B2 publication Critical patent/AU2017298648B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017298648A 2016-07-18 2017-07-16 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein Active AU2017298648B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363712P 2016-07-18 2016-07-18
US62/363,712 2016-07-18
PCT/IB2017/054293 WO2018015861A1 (en) 2016-07-18 2017-07-16 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein

Publications (2)

Publication Number Publication Date
AU2017298648A1 AU2017298648A1 (en) 2019-01-31
AU2017298648B2 true AU2017298648B2 (en) 2023-05-11

Family

ID=59399457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017298648A Active AU2017298648B2 (en) 2016-07-18 2017-07-16 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein

Country Status (12)

Country Link
US (1) US20190282560A1 (https=)
EP (1) EP3484475B1 (https=)
JP (1) JP2019521160A (https=)
CN (1) CN109562108A (https=)
AU (1) AU2017298648B2 (https=)
DK (1) DK3484475T3 (https=)
ES (1) ES2967074T3 (https=)
FI (1) FI3484475T3 (https=)
MX (1) MX389845B (https=)
PL (1) PL3484475T3 (https=)
RU (1) RU2744615C2 (https=)
WO (1) WO2018015861A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN112294786A (zh) * 2019-08-01 2021-02-02 深圳大学 一种含乙胺丁醇与他汀类药物的抗结核组合药物
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
WO2022047730A1 (en) * 2020-09-04 2022-03-10 Shanghai Pharmaceuticals Holding Co., Ltd. Methods to treat inflammatory bowel disease
EP4213821A2 (en) * 2020-09-21 2023-07-26 The Regents of the University of California Immunological effects of metabolites

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007074406A2 (en) * 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT131118B (de) 1929-04-19 1933-01-10 Ig Farbenindustrie Ag Verfahren zur Darstellung von N-Methylpyridiniumchlorid.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3614408A (en) 1969-02-20 1971-10-19 British Petroleum Co Waveform analyzing system, particularly for chromatographs, wherein the waveform is integrated between selected peaks and valleys
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4115390A (en) 1977-08-19 1978-09-19 Nardi John C Method for the preparation of 1-alkyl pyridinium chlorides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
CA2629913A1 (en) * 2005-12-09 2007-06-14 Cerecon Ag Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
PL2211858T3 (pl) * 2007-10-12 2015-06-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
WO2009137527A1 (en) * 2008-05-06 2009-11-12 Cortria Corporation 1-methylnicotinamide analogs
WO2011047358A1 (en) * 2009-10-15 2011-04-21 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2007074406A2 (en) * 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
WO2007103540A2 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Also Published As

Publication number Publication date
PL3484475T3 (pl) 2024-03-11
FI3484475T3 (fi) 2023-12-12
MX389845B (es) 2025-03-20
ES2967074T3 (es) 2024-04-25
RU2019104343A3 (https=) 2020-09-17
MX2019000721A (es) 2019-06-10
US20190282560A1 (en) 2019-09-19
RU2019104343A (ru) 2020-08-18
JP2019521160A (ja) 2019-07-25
CA3030805A1 (en) 2018-01-25
DK3484475T3 (da) 2023-11-27
AU2017298648A1 (en) 2019-01-31
EP3484475B1 (en) 2023-09-27
WO2018015861A1 (en) 2018-01-25
EP3484475A1 (en) 2019-05-22
RU2744615C2 (ru) 2021-03-11
CN109562108A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
AU2017298648B2 (en) 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
Attaway et al. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature
JP2021008475A (ja) Ｈｅｒ２増幅性癌の処置のための方法
US9532984B2 (en) Therapeutic combination for cancer treatment
CN105228453B (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
US20140178366A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
TW201605455A (zh) Ｂｅｔ抑制劑與布魯頓氏酪胺酸激酶抑制劑之組合
IL268138B (en) Combinations of cabozantinib and atezolizumab to treat cancer
TW201628622A (zh) Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
KR20180004263A (ko) 염증 또는 신경병성 통증의 치료 방법
JP2023510604A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
WO2014031769A2 (en) Treatment of diseases associated with inflammation
EP2849853A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
SG11202109854RA (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
KR102747348B1 (ko) 경구 리파마이신 sv 조성물
World Health Organization WHO pharmaceuticals newsletter: 2013, No. 5
JP2025502266A (ja) 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法
WO2015187848A1 (en) Hdac inhibitor and btk inhibitor combinations
CA3030805C (en) 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein
Hopewell Treatment of tuberculosis
JP2025000672A (ja) Ｌｏｕ０６４を使用した治療の方法
US20200360331A1 (en) COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
EP4168027A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
RU2729425C2 (ru) Дозы панобиностата для множественной миеломы
US12600715B2 (en) Soluble guanylate cyclate activators for treating systemic sclerosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)